TD Cowen raises Twist Bioscience price target to $89

0 min read | Published on 15 Jun 2026, 10:32 PM |Updated on 15 Jun 2026, 10:32 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

TD Cowen analyst Brendan Smith maintained a Buy rating on Twist Bioscience and increased the price target from $68 to $89, indicating a positive outlook for the stock.

*this image is generated using AI for illustrative purposes only.

TD Cowen analyst Brendan Smith has maintained a Buy rating on Twist Bioscience (NASDAQ: TWST) and raised the price target to $89, signaling increased confidence in the stock's potential. The previous target was $68. This adjustment reflects a revised outlook on the company's valuation and growth prospects.

The rating and price target update provide investors with a revised benchmark for the stock's performance. Twist Bioscience operates in the synthetic biology sector, utilizing its platform to write DNA for various applications.

Metric	Value
Rating	Buy
Previous Price Target	$68
New Price Target	$89

What specific catalysts or milestones does TD Cowen expect to drive Twist Bioscience's growth to meet the new $89 price target?

How might this revised valuation impact investor sentiment and trading volume for Twist Bioscience in the short term?

What are the potential competitive risks or market challenges that could hinder Twist Bioscience from achieving this updated outlook?

Canaccord Genuity initiates coverage on Twist Bioscience with Buy rating

0 min read | Published on 15 Jun 2026, 10:10 PM |Updated on 15 Jun 2026, 10:10 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Canaccord Genuity analyst Kyle Mikson initiated coverage on Twist Bioscience with a Buy rating and a price target of $90, signaling a positive outlook for the stock.

*this image is generated using AI for illustrative purposes only.

Canaccord Genuity analyst Kyle Mikson has initiated coverage on Twist Bioscience with a Buy rating and announced a price target of $90. The rating reflects a positive outlook on the company's performance and future prospects.

Coverage Details

The initiation of coverage provides a new assessment of Twist Bioscience's market position. The price target of $90 indicates the firm's expectation for the stock's potential upside.

Analyst Perspective

Kyle Mikson's Buy rating suggests confidence in the company's ability to deliver value to shareholders. The detailed report supporting this rating likely outlines the key drivers behind the positive stance.

Twist Bioscience is now on the radar of investors following this coverage initiation. The price target serves as a benchmark for evaluating the stock's performance in the coming months.

What specific catalysts does Mikson identify that could drive Twist Bioscience's stock toward the $90 price target?

How might this new coverage impact investor sentiment and trading volume for Twist Bioscience in the short term?

What are the potential risks or challenges that could hinder the company from achieving the projected upside?